Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Ross Camidge, a leading thoracic medical oncologist from the University of Colorado, to discuss the recent approval of telisotuzumab-vedotin (Teliso-V) for metastatic non-small cell lung cancer (NSCLC) with C-met overexpression, based on the LUMINOSITY trial.
Join us as we explore: 
• The mechanism of action of telisotuzumab and its role as an antibody-drug conjugate. 
• The prevalence of C-met overexpression in NSCLC and its implications for testing and treatment. 
• Key findings from the Luminosity trial, including response rates and study design. 
• The importance of C-met testing in clinical practice. 
• Management of side effects associated with telisotuzumab, particularly peripheral neuropathy.
Follow us on social media: 
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers 
•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers 
•⁠  Website: https://oncbrothers.com/
This episode is packed with valuable insights for oncologists and healthcare professionals navigating the evolving landscape of lung cancer treatment. Don't miss out on this informative discussion!

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Ross Camidge, a leading thoracic medical oncologist from the University of Colorado, to discuss the recent approval of telisotuzumab-vedotin (Teliso-V) for metastatic non-small cell lung cancer (NSCLC) with C-met overexpression, based on the LUMINOSITY trial. Join us as we explore: • The mechanism of action of telisotuzumab and its role as an antibody-drug conjugate. • The prevalence of C-met overexpression in NSCLC and its implications for testing and treatment. • Key findings from the Luminosity trial, including response rates and study design. • The importance of C-met testing in clinical practice. • Management of side effects associated with telisotuzumab, particularly peripheral neuropathy. Follow us on social media: •⁠ ⁠X/Twitter: https://twitter.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ This episode is packed with valuable insights for oncologists and healthcare professionals navigating the evolving landscape of lung cancer treatment. Don't miss out on this informative discussion!

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Ross Camidge, a leading thoracic medical oncologist from the University of Colorado, to discuss the recent approval of telisotuzumab-vedotin (Teliso-V) for metastatic non-small cell lung cancer (NSCLC) with C-met overexpression, based on the LUMINOSITY trial.
Join us as we explore: 
• The mechanism of action of telisotuzumab and its role as an antibody-drug conjugate. 
• The prevalence of C-met overexpression in NSCLC and its implications for testing and treatment. 
• Key findings from the Luminosity trial, including response rates and study design. 
• The importance of C-met testing in clinical practice. 
• Management of side effects associated with telisotuzumab, particularly peripheral neuropathy.
Follow us on social media: 
•⁠ &nbsp;⁠X/Twitter: https://twitter.com/oncbrothers 
•⁠ &nbsp;⁠Instagram: https://www.instagram.com/oncbrothers 
•⁠ &nbsp;Website: https://oncbrothers.com/
This episode is packed with valuable insights for oncologists and healthcare professionals navigating the evolving landscape of lung cancer treatment. Don't miss out on this informative discussion!

FDA Approval of Telisotuzumab (Teliso-V) in c-MET Overexpression - LUMINOSITY trial

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology &amp; oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology &amp; oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at <a href="mailto:info@oncbrothers.com">info@oncbrothers.com</a>
Privacy Policy: <a href="https://oncbrothers.com/privacy-policy">https://oncbrothers.com/privacy-policy</a>
Terms &amp; Conditions: <a href="https://oncbrothers.com/terms-and-conditions">https://oncbrothers.com/terms-and-conditions</a>

Medicine

Health & Fitness

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com Privacy Policy: https://oncbrothers.com/privacy-policy Terms & Conditions: https://oncbrothers.com/terms-and-conditions

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology &amp; oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients. Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities. If you want to navigate the complexities of your hematology &amp; oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at <a href="mailto:info@oncbrothers.com" rel="noopener noreferrer">info@oncbrothers.com</a>
Privacy Policy: <a href="https://oncbrothers.com/privacy-policy" rel="noopener noreferrer">https://oncbrothers.com/privacy-policy</a>
Terms &amp; Conditions: <a href="https://oncbrothers.com/terms-and-conditions" rel="noopener noreferrer">https://oncbrothers.com/terms-and-conditions</a>

Share FDA Approval of Telisotuzumab (Teliso-V) in c-MET Overexpression - LUMINOSITY trial

Sign up to save your podcasts

FDA Approval of Telisotuzumab (Teliso-V) in c-MET Overexpression - LUMINOSITY trial

FDA Approval of Telisotuzumab (Teliso-V) in c-MET Overexpression - LUMINOSITY trial

More shows like Oncology Brothers: Practice-Changing Cancer Discussions

NEJM This Week

Journal of Clinical Oncology (JCO) Podcast

Research To Practice | Oncology Videos

ASCO Daily News

Mayo Clinic Talks

White Coat Investor Podcast

The Curbsiders Internal Medicine Podcast

Core IM | Internal Medicine Podcast

The ONS Podcast

OncoPharm

ASCO Guidelines

OncLive® On Air

Becker’s Healthcare Podcast

Oncology Today with Dr Neil Love

Two Onc Docs